Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jan 12, 2024
Smart Investing: $TLRY Rakes in +5.02% Profits via Automated Trading.

Smart Investing: $TLRY Rakes in +5.02% Profits via Automated Trading.

Artificial intelligence-powered trading robots have been making waves, demonstrating their capabilities in the volatile world of finance. At "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," these AI-driven bots successfully generated a remarkable +5.02% gain while trading TLRY over the previous week. In this article, we delve into the technical analysis of TLRY's recent performance, focusing on key indicators, earnings results, market capitalization, and notable price and volume movements within the Pharmaceuticals: Other Industry.

Technical Indicator Insights: TLRY's RSI Oscillator

One notable technical signal for TLRY is the movement of its 10-day Relative Strength Index (RSI) Oscillator. On December 29, 2023, the RSI moved out of the overbought zone, suggesting a potential shift from an upward to a downward trend. According to Tickeron's A.I.dvisor, in 15 out of 16 instances where the RSI exited the overbought zone, the stock moved lower in the subsequent days. This statistical pattern places the odds of a downward move at a substantial 90%. Traders are advised to consider selling the stock or exploring put options in response to this signal.

Earnings Report Overview: January 09, 2024

TLRY's latest earnings report, dated January 09, 2024, revealed earnings per share of -7 cents, falling short of the estimated -5 cents. The company, with 12.73 million shares outstanding, currently holds a market capitalization of 1.29 billion. Analyzing the earnings miss and its impact on the stock's valuation provides valuable insights for investors considering their positions in TLRY.

Market Capitalization Comparison in Pharmaceuticals: Other Industry

Comparing TLRY's market capitalization with industry peers is crucial for understanding its relative standing. In the Pharmaceuticals: Other Industry, the average market capitalization is 2.79 billion, with a range spanning from 246 million (PEMTF) to a staggering 82.08 billion (ZTS). TLRY's position within this spectrum influences its attractiveness to investors and potential for future growth.

Price Movement Metrics: Highs, Lows, and Industry Averages

Analyzing TLRY's price movements alongside industry benchmarks provides context for evaluating its performance. The average weekly, monthly, and quarterly price growth across all stocks in the Pharmaceuticals: Other Industry stands at 0%, 34%, and 21%, respectively. TLRY's individual price trajectory becomes more apparent when compared to its industry counterparts, offering insights into its relative strength and weaknesses.

Notable high and low price movements within the industry further highlight TLRY's performance. With UPC experiencing the highest price growth at 66%, and CNGGF witnessing a significant fall at -52%, understanding these extremes aids in contextualizing TLRY's own price dynamics.

Volume Trends in Pharmaceuticals: Other Industry

Examining TLRY's trading volume alongside industry trends is essential for assessing investor sentiment. The average weekly, monthly, and quarterly volume growth across all stocks in the Pharmaceuticals: Other Industry is -3%, 34%, and -17%, respectively. TLRY's volume trends, compared to industry averages, provide valuable insights into the level of interest and activity surrounding the stock.

In summary, the technical analysis of TLRY's recent performance, encompassing indicators, earnings results, market capitalization, price movements, and volume trends, offers investors a comprehensive understanding of the stock's current position and potential future trajectory.

Related Ticker: TLRY

Contributor

Dem Sem's AvatarDem Sem|Expert

Momentum Indicator for TLRY turns positive, indicating new upward trend

TLRY saw its Momentum Indicator move above the 0 level on August 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned positive. In of the 77 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

TLRY moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for TLRY crossed bullishly above the 50-day moving average on August 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 117 cases where TLRY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TLRY broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.384) is normal, around the industry mean (46.946). P/E Ratio (0.000) is within average values for comparable stocks, (93.744). TLRY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.000). TLRY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (0.550) is also within normal values, averaging (176.799).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.12B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 38%. RDHL experienced the highest price growth at 44%, while IMCC experienced the biggest fall at -97%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was -26% and the average quarterly volume growth was -11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 55
SMR Rating: 88
Profit Risk Rating: 82
Seasonality Score: -16 (-100 ... +100)
View a ticker or compare two or three
TLRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
1600
Web
https://www.tilray.com
Interact to see
Advertisement
Payoneer Global (PAYO) fell more than 18% today after it missed Wall Street expectations on both Q4 2025 revenue and earnings, and issued softer‑than‑hoped guidance that reinforced concerns about slowing growth and competitive pressure in cross‑border fintech.
Gold, uranium, and rare earth stocks are moving fast in 2026 — and this 15-minute AI Trading Agent is built to move faster. Designed for high-beta Mining & Metals leaders like NEM, LEU, MP, and KGC, it transforms commodity volatility into structured, data-driven opportunity with institutional-grade risk control.
In a market where milliseconds matter and emotional decisions cost fortunes, a new class of AI-driven trading tools is rewriting the rulebook. Meet the HUBB, AVGO, ITA, QQQ – Trading Results AI Trading Agent (4 Tickers, 5min) — a precision-engineered robot that monitors four strategically selected tickers across semiconductors, industrial power infrastructure, aerospace & defense, and broad tech growth.
Q4 2025 gross profit grew about 24% year over year to roughly 2.87 billion dollars, with Cash App gross profit up about 33% and Square gross profit up around 7%. Adjusted operating income jumped to about 588 million dollars in Q4 (around a 20% margin), up strongly from the prior year. For the full year, gross profit was roughly 10.36 billion dollars, up about 17% year over year, showing broad‑based growth across the business.
NVDA shares declined 5.47% on Thursday, February 26, 2026, closing at $184.87, down from the prior session close of approximately $195.56. The primary catalyst was a "sell the news" reaction to Q4 fiscal 2026 earnings that beat estimates on every headline metric but failed to ignite meaningful buying interest.
Shares of UHS fell approximately 9.15% on February 26, 2026, closing near $209.62, down from a prior close of $230.73. The primary catalyst was a mixed Q4 2025 earnings report: adjusted EPS of $5.88 missed the consensus estimate of $5.92, and revenue of $4.49 billion fell short of the $4.50–$4.51 billion analyst forecast.
HEI shares fell approximately 9.21% on February 26, 2026, closing at $312.98 versus a prior close near $344.72. The primary catalyst was HEICO's Q1 fiscal 2026 earnings report, which delivered headline beats on EPS and revenue but disappointed investors on margin quality, Adjusted EBITDA, and cash flow generation.
IONQ surged +21.70% on February 26, 2026, closing at $40.88 versus the prior session's close of $33.59. The primary catalyst was a powerful Q4 and full-year 2025 earnings beat, with annual revenue of $130 million coming in 20% above guidance and representing 202% year-over-year growth.
Shares of CRWV declined approximately 11.38% in Friday's session, falling from a prior close of $97.63 to around $86.52, after the company reported Q4 2025 earnings after the bell on Thursday, February 26. The primary catalyst was a wider-than-expected net loss of $0.56 per share on EPS expectations of −$0.49, alongside a massive capex plan calling for $30–$35 billion in infrastructure spending in 2026, more than doubling the prior year.
DELL shares surged 16.64% during Friday's session, last trading around $141.65, up from the prior close of $121.45. The primary catalyst was a blowout Q4 fiscal year 2026 earnings report, with revenue of $33.4 billion — up 39% year-over-year — beating consensus estimates by roughly $2 billion.
Stifel Financial (SF) appears to be down over 30% on your screen today primarily because its shares began trading split‑adjusted following a three‑for‑two stock split (a 50% stock dividend), not because of a sudden collapse in the company’s fundamentals. After the split, the per‑share price is mechanically lower, even though the underlying value of the business has not changed.
Sunrun (RUN) sank more than 35–37% today even after posting a massive Q4 beat because its outlook and strategic commentary signaled slower volume growth, tighter financing conditions, and a more defensive stance on 2026, which together triggered a sharp reset in already‑volatile solar sentiment.
PAR Technology Corp. (PAR) dropped more than 28% today after its latest earnings report, even though it beat on revenue and EPS, because investors focused on weak profitability, continued operating losses, and a wave of sharply lower analyst price targets that signaled reduced confidence in the stock’s near‑term upside.
Carter’s (CRI) dropped more than 21% today because, even though it beat Q4 expectations on both sales and earnings, management issued a much weaker 2026 earnings outlook, highlighted ongoing margin pressure from tariffs and product costs, and guided to a sharp near‑term EPS drop that jarred investors.
WES is an oil & gas midstream partnership (NYSE: WES) with largely fee‑based, long‑term volume contracts in key basins such as the Delaware and DJ, which insulate cash flows from direct oil price swings but still tie them to producer activity and throughput. Current positioning: The units trade around 41–42 dollars with a high cash yield (roughly 9% dividend), solid profitability (P/E about 14), and strong returns on equity above 40%, signaling a mature, cash‑generative infrastructure asset.
SD is a pure‑play upstream energy company with operations concentrated in U.S. onshore oil and gas, so its revenues are directly influenced by global oil and gas price movements.
TTI is an oilfield services and specialty chemicals company, not a direct oil producer, so it tends to benefit when higher oil prices lead to sustained drilling and completion activity rather than from price moves alone. The Iran war raises the odds of major supply disruptions, and several commentators see a path to Brent near 100 dollars per barrel if the Strait of Hormuz is impaired, which would support energy capex and, by extension, demand for TTI’s services and fluids.
COP is a global upstream heavyweight, producing more than 2.3 million barrels of oil equivalent per day and generating over 60 billion dollars in annual revenue, with a strategy centered on disciplined capex and robust cash returns to shareholders. The Iran war introduces a structural risk premium into oil markets; if supply from the region or traffic through Hormuz is disrupted, analysts see Brent potentially trading nearer 90–100 dollars per barrel or higher, which is supportive for ConocoPhillips’ cash flows and valuation.
ONEOK is a diversified midstream operator focused on gathering, processing, fractionation, transportation, storage, and marine export of natural gas, NGLs, refined products, and crude, with most revenue coming from relatively stable fee‑based contracts. The US–Iran war increases the odds of supply disruptions or perceived risks in the Gulf, which has already contributed to higher oil and LNG prices and a persistent geopolitical risk premium.
Exxon Mobil is a global energy giant with roughly 324 billion dollars in trailing revenue, around 29 billion dollars in earnings, record production near 4.7 million barrels per day, and a long runway of projects in Guyana, the Permian, LNG and carbon capture. The Iran war has disrupted shipping through the Strait of Hormuz and could keep a 10–20 dollar‑per‑barrel risk premium in crude if tensions stay high, which would generally be positive for XOM’s upstream earnings and refining margins.